These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 35125080)

  • 1. An Unfolded Protein Response-Related mRNA Signature Predicting the Survival and Therapeutic Effect of Hepatocellular Carcinoma.
    Su Z; Wang L; Chen X; Zhong X; Wang D; Wang J; Shao L; Chen G; Wu J
    Comb Chem High Throughput Screen; 2022; 25(12):2046-2058. PubMed ID: 35125080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma.
    Zhang S; Guo H; Wang H; Liu X; Wang M; Liu X; Fan Y; Tan K
    Apoptosis; 2024 Jun; 29(5-6):768-784. PubMed ID: 38493408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
    Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
    Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
    Yan Z; He M; He L; Wei L; Zhang Y
    Front Immunol; 2021; 12():723271. PubMed ID: 34925311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
    Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
    Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mining prognostic markers of Asian hepatocellular carcinoma patients based on the apoptosis-related genes.
    Yan J; Cao J; Chen Z
    BMC Cancer; 2021 Feb; 21(1):175. PubMed ID: 33602168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of a Novel Oxidative Stress Response-Related Gene Signature for Predicting the Prognosis and Therapeutic Responses in Hepatocellular Carcinoma.
    Hong J; Cai X
    Dis Markers; 2022; 2022():6201987. PubMed ID: 36133439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma.
    Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM
    BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
    Li X; Lin J; Pan Y; Cui P; Xia J
    Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
    [No Abstract]   [Full Text] [Related]  

  • 14. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment.
    Wei S; Tan J; Huang X; Zhuang K; Qiu W; Chen M; Ye X; Wu M
    J Transl Med; 2024 Jul; 22(1):711. PubMed ID: 39085893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hypoxia-related signature for clinically predicting diagnosis, prognosis and immune microenvironment of hepatocellular carcinoma patients.
    Zhang B; Tang B; Gao J; Li J; Kong L; Qin L
    J Transl Med; 2020 Sep; 18(1):342. PubMed ID: 32887635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients.
    Lv W; Yao Q
    Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
    Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
    BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.